Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
BILLERICA, Mass. - On Monday, Bruker Corporation (NASDAQ:BRKR) reported second-quarter earnings that missed analyst expectations and significantly reduced its full-year outlook, citing challenging demand conditions across multiple markets.
The scientific instrument maker’s shares fell 7.84% in pre-market trading after the earnings release.
The company reported second-quarter adjusted earnings of $0.32 per share, falling well short of the $0.42 analyst consensus. Revenue came in at $797.4 million, below the expected $812.81 million and down 0.4% YoY. Organic revenue declined 7.0% compared to the same period last year.
"Life-science research instruments demand is under pressure at the moment," said Frank H. Laukien, Bruker’s President and CEO. "Our second quarter came in below expectations, as we experienced challenging demand conditions in the US academic market, as well as in biopharma and industrial markets."
In response to the difficult operating environment, Bruker announced an expanded cost savings initiative expected to reduce annual costs by $100-$120 million in fiscal 2026. The company also slashed its full-year 2025 guidance, now projecting revenue of $3.43-$3.50 billion (previously $3.52 billion consensus) and adjusted EPS of $1.95-$2.05, well below the $2.42 analyst estimate and down from $2.41 in fiscal 2024.
The company’s operating margin deteriorated significantly, with non-GAAP operating margin falling to 9.0% in Q2 2025 from 13.8% in the year-ago period.
Laukien expressed optimism for a partial demand recovery in fiscal 2026, noting the company’s "successful track record of rebounding very strongly from previous market disruptions." However, the immediate outlook remains challenging as Bruker works to gain "improved visibility into US academic funding trends, China stimulus, finalized tariffs, as well as into the timing of a recovery in biopharma drug discovery and industrial research instruments demand."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.